At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer
In Brief
A Phase 3 clinical trial evaluating Durvalumab, Cisplatin, and 2 other interventions for Locally Advanced Cervical Cancer. Completed, enrolled 770 participants across 117 sites in 15 countries.
Detailed Summary
This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer
Study Details
Timeline
Interventions
IV infusion every 4 weeks
Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
For patients enrolled under CSP v2 and prior - platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
Radiation therapy per standard of care